News & Insights

Sign up to our newsletter Subscribe

Subscribe

Close

Research & Publications
News & Insights
Education
Innovation Policy Prize

Subscribe

Latest Research & Publications

What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

#image_title

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

00
15
16
17
18
19
20
21
22
23
00

Close

Subscribe

News & Insights

Latest Research & Publications

What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

All Publications

OHE Newsroom

Applications open for MSc Fellowship Programme 2025

A switch to vegan diets could save the NHS £6.7 billion per year, new research reveals

Filter results by

Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions: Opportunities, Challenges and Unresolved Questions

Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance

Invitation to OHE’s Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?

Is There Societal Support for an End of Life Premium?

HTAi Asia Policy Forum Briefing Papers: Value and Affordability, Transferability, and Delivery of High Quality HTA for Decision Making

Do People of Different Ages Value Health Differently?

Promoting Evidence-based Health Care Policy in Spain: 6th Annual Workshop with EvaluAES

OHE is Pleased to Announce the Appointment of a New Economist: David Mott

New Paper in Quality of Life Research – Can Patients’ Self-Reported Pain be Compared and Aggregated in Multi-Country Studies?

How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?

OHE Lunchtime Seminar and Webinar with Professor David Grabowski: Interventions that Encourage High-Value Nursing Home Care: Lessons for the UK

EQ-5D and the EuroQol Group: Past, Present and Future

Subscribe To Our Newsletter

Share on Mastodon